Shaping the murine macrophage phenotype: IL-4 and cyclic AMP synergistically activate the arginase I promoter

Journal of Immunology

Volumn 191, Issue 5, 2013, Pages 2290-2298

  Sheldon, Kathryn E ^a,c   Shandilya, Harish ^a,d   Kepka Lenhart, Diane ^a   Poljakovic, Mirjana ^a,e,f   Ghosh, Arundhati ^b   Morris Jr , Sidney M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

^d Intas Biopharmaceuticals Ltd   (India)

^e KAROLINSKA INSTITUTE   (Sweden)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

8 BROMO CYCLIC AMP; ARGINASE 1; CCAAT ENHANCER BINDING PROTEIN BETA; CYCLIC AMP; INTERLEUKIN 4; MESSENGER RNA; STAT6 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARGINASE I GENE; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL ACTIVITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LOCALIZATION; GENE; GENE FUNCTION; GENE IDENTIFICATION; MACROPHAGE FUNCTION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANIMALS; ARGINASE; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; CYCLIC AMP; GENE EXPRESSION REGULATION; IMMUNOBLOTTING; INTERLEUKIN-4; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; PHENOTYPE; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; TRANSFECTION;

EID: 84883388451     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202102     Document Type: Article

References (63)

1. Goerdt, S., O. Politz, K. Schledzewski, R. Birk, A. Gratchev, P. Guillot, N. Hakiy, C. D. Klemke, E. Dippel, V. Kodelja, and C. E. Orfanos. 1999. Alternative versus classical activation of macrophages. Pathobiology 67: 222-226.
2. Gordon, S. 2003. Alternative activation of macrophages. Nat. Rev. Immunol. 3: 23-35.
3. Stein, M., S. Keshav, N. Harris, and S. Gordon. 1992. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J. Exp. Med. 176: 287-292.
4. Martinez, F. O., L. Helming, and S. Gordon. 2009. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 27: 451-483.
5. Mills, C. D., K. Kincaid, J. M. Alt, M. J. Heilman, and A. M. Hill. 2000. M-1/M-2 macrophages and the Th1/Th2 paradigm. J. Immunol. 164: 6166-6173.
6. Granger, D. L., J. B. Hibbs, Jr., J. R. Perfect, and D. T. Durack. 1990. Metabolic fate of L-arginine in relation to microbiostatic capability of murine macrophages. J. Clin. Invest. 85: 264-273.
7. Mosser, D. M. 2003. The many faces of macrophage activation. J. Leukoc. Biol. 73: 209-212.
8. Stout, R. D., and J. Suttles. 2004. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J. Leukoc. Biol. 76: 509-513.
9. Mantovani, A., A. Sica, P. Allavena, C. Garlanda, and M. Locati. 2009. Tumorassociated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum. Immunol. 70: 325-330.
10. Stables, M. J., S. Shah, E. B. Camon, R. C. Lovering, J. Newson, J. Bystrom, S. Farrow, and D. W. Gilroy. 2011. Transcriptomic analyses of murine resolution-phase macrophages. Blood 118: e192-208.
11. Bernard, A. C., E. A. Fitzpatrick, M. E. Maley, G. L. Gellin, B. J. Tsuei, W. A. Arden, B. R. Boulanger, P. A. Kearney, and J. B. Ochoa. 2000. Beta adrenoceptor regulation of macrophage arginase activity. Surgery 127: 412-418.
12. Corraliza, I. M., G. Soler, K. Eichmann, and M. Modolell. 1995. Arginase induction by suppressors of nitric oxide synthesis (IL-4, IL-10 and PGE2) in murine bone-marrow-derived macrophages. Biochem. Biophys. Res. Commun. 206: 667-673.
13. Csóka, B., Z. Selmeczy, B. Koscsó, Z. H. Németh, P. Pacher, P. J. Murray, D. Kepka-Lenhart, S. M. Morris, Jr., W. C. Gause, S. J. Leibovich, and G. Haskó. 2012. Adenosine promotes alternative macrophage activation via A2A and A2B receptors. FASEB J. 26: 376-386.
14. Barksdale, A. R., A. C. Bernard, M. E. Maley, G. L. Gellin, P. A. Kearney, B. R. Boulanger, B. J. Tsuei, and J. B. Ochoa. 2004. Regulation of arginase expression by T-helper II cytokines and isoproterenol. Surgery 135: 527-535.
15. Erdely, A., D. Kepka-Lenhart, M. Clark, P. Zeidler-Erdely, M. Poljakovic, W. J. Calhoun, and S. M. Morris, Jr. 2006. Inhibition of phosphodiesterase 4 amplifies cytokine-dependent induction of arginase in macrophages. Am. J. Physiol. Lung Cell. Mol. Physiol. 290: L534-L539.
16. Chang, C. I., B. Zoghi, J. C. Liao, and L. Kuo. 2000. The involvement of tyrosine kinases, cyclic AMP/protein kinase A, and p38 mitogen-activated protein kinase in IL-13-mediated arginase I induction in macrophages: its implications in IL-13-inhibited nitric oxide production. J. Immunol. 165: 2134-2141.
17. Pauleau, A. L., R. Rutschman, R. Lang, A. Pernis, S. S. Watowich, and P. J. Murray. 2004. Enhancer-mediated control of macrophage-specific arginase I expression. J. Immunol. 172: 7565-7573.
18. Gray, M. J., M. Poljakovic, D. Kepka-Lenhart, and S. M. Morris, Jr. 2005. Induction of arginase I transcription by IL-4 requires a composite DNA response element for STAT6 and C/EBPβ. Gene 353: 98-106.
19. Odegaard, J. I., R. R. Ricardo-Gonzalez, M. H. Goforth, C. R. Morel, V. Subramanian, L. Mukundan, A. Red Eagle, D. Vats, F. Brombacher, A. W. Ferrante, and A. Chawla. 2007. Macrophage-specific PPARg controls alternative activation and improves insulin resistance. Nature 447: 1116-1120.
20. Liao, X., N. Sharma, F. Kapadia, G. Zhou, Y. Lu, H. Hong, K. Paruchuri, G. H. Mahabeleshwar, E. Dalmas, N. Venteclef, et al. 2011. Krüppel-like factor 4 regulates macrophage polarization. J. Clin. Invest. 121: 2736-2749.
21. Albina, J. E., E. J. Mahoney, J. M. Daley, D. E. Wesche, S. M. Morris, Jr., and J. S. Reichner. 2005. Macrophage arginase regulation by CCAAT/enhancerbinding protein beta. Shock 23: 168-172.
22. Zhang, X., R. Goncalves, and D. Mosser. 2008. The isolation and characterization of murine macrophages. Curr. Protoc. Immunol. Chapter 14: Unit 14.1.
23. -ΔΔC(T) method. Methods 25: 402-408.
24. Bradley, M. N., L. Zhou, and S. T. Smale. 2003. C/EBPβ regulation in lipopolysaccharide-stimulated macrophages. Mol. Cell. Biol. 23: 4841-4858.
25. 299. J. Biol. Chem. 272: 30356-30361.
26. Vats, D., L. Mukundan, J. I. Odegaard, L. Zhang, K. L. Smith, C. R. Morel, R. A. Wagner, D. R. Greaves, P. J. Murray, and A. Chawla. 2006. Oxidative metabolism and PGC-1β attenuate macrophage-mediated inflammation. Cell Metab. 4: 13-24.
27. Sharda, D. R., S. Yu, M. Ray, M. L. Squadrito, M. De Palma, T. A. Wynn, S. M. Morris, Jr., and P. A. Hankey. 2011. Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase. J. Immunol. 187: 2181-2192.
28. Munder, M., K. Eichmann, J. M. Morán, F. Centeno, G. Soler, and M. Modolell. 1999. Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J. Immunol. 163: 3771-3777.
29. Bronte, V., P. Serafini, C. De Santo, I. Marigo, V. Tosello, A.Mazzoni, D.M. Segal, C. Staib, M. Lowel, G. Sutter, et al. 2003. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J. Immunol. 170: 270-278.
30. Rodriguez, P. C., C. P. Hernandez, D. Quiceno, S. M. Dubinett, J. Zabaleta, J. B. Ochoa, J. Gilbert, and A. C. Ochoa. 2005. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med. 202: 931-939.
31. + T cells. J. Clin. Invest. 116: 2777-2790.
32. Highfill, S. L., P. C. Rodriguez, Q. Zhou, C. A. Goetz, B. H. Koehn, R. Veenstra, P. A. Taylor, A. Panoskaltsis-Mortari, J. S. Serody, D. H. Munn, et al. 2010. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood 116: 5738-5747.
33. Ramji, D. P., and P. Foka. 2002. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem. J. 365: 561-575.
34. Kowenz-Leutz, E., G. Twamley, S. Ansieau, and A. Leutz. 1994. Novel mechanism of C/EBP beta (NF-M) transcriptional control: activation through derepression. Genes Dev. 8: 2781-2791.
35. Lee, S., M. Miller, J. D. Shuman, and P. F. Johnson. 2010. CCAAT/enhancerbinding protein β DNA binding is auto-inhibited by multiple elements that also mediate association with p300/CREB-binding protein (CBP). J. Biol. Chem. 285: 21399-21410.
36. Lee, S., J. D. Shuman, T. Guszczynski, K. Sakchaisri, T. Sebastian, T. D. Copeland, M. Miller, M. S. Cohen, J. Taunton, R. C. Smart, et al. 2010. RSK-mediated phosphorylation in the C/EBPβ leucine zipper regulates DNA binding, dimerization, and growth arrest activity. Mol. Cell. Biol. 30: 2621-2635.
37. Metz, R., and E. Ziff. 1991. cAMP stimulates the C/EBP-related transcription factor rNFIL-6 to trans-locate to the nucleus and induce c-fos transcription. Genes Dev. 5: 1754-1766.
38. Pesu, M., K. Takaluoma, S. Aittomäki, A. Lagerstedt, K. Saksela, P. E. Kovanen, and O. Silvennoinen. 2000. Interleukin-4-induced transcriptional activation by Stat6 involves multiple serine/threonine kinase pathways and serine phosphorylation of stat6. Blood 95: 494-502.
39. Wick, K. R., and M. T. Berton. 2000. IL-4 induces serine phosphorylation of the STAT6 transactivation domain in B lymphocytes. Mol. Immunol. 37: 641-652.
40. Wang, Y., M. G. Malabarba, Z. S. Nagy, and R. A. Kirken. 2004. Interleukin 4 regulates phosphorylation of serine 756 in the transactivation domain of Stat6. Roles for multiple phosphorylation sites and Stat6 function. J. Biol. Chem. 279: 25196-25203.
41. Shankaranarayanan, P., P. Chaitidis, H. Kühn, and S. Nigam. 2001. Acetylation by histone acetyltransferase CREB-binding protein/p300 of STAT6 is required for transcriptional activation of the 15-lipoxygenase-1 gene. J. Biol. Chem. 276: 42753-42760.
42. Chen, W., M. O. Daines, and G. K. Hershey. 2004. Methylation of STAT6 modulates STAT6 phosphorylation, nuclear translocation, and DNA-binding activity. J. Immunol. 172: 6744-6750.
43. Serrat, N., S. Pereira-Lopes, M. Comalada, J. Lloberas, and A. Celada. 2012. Deacetylation of C/EBPβ is required for IL-4-induced arginase-1 expression in murine macrophages. Eur. J. Immunol. 42: 3028-3037.
44. Chen, H. C., and N. C. Reich. 2010. Live cell imaging reveals continuous STAT6 nuclear trafficking. J. Immunol. 185: 64-70.
45. Fiering, S., J. P. Northrop, G. P. Nolan, P. S. Mattila, G. R. Crabtree, and L. A. Herzenberg. 1990. Single cell assay of a transcription factor reveals a threshold in transcription activated by signals emanating from the T-cell antigen receptor. Genes Dev. 4: 1823-1834.
46. Hume, D. A. 2000. Probability in transcriptional regulation and its implications for leukocyte differentiation and inducible gene expression. Blood 96: 2323-2328.
47. Ford, E., and D. Thanos. 2010. The transcriptional code of human IFN-β gene expression. Biochim. Biophys. Acta 1799: 328-336.
48. Merika, M., A. J. Williams, G. Chen, T. Collins, and D. Thanos. 1998. Recruitment of CBP/p300 by the IFNβ enhanceosome is required for synergistic activation of transcription. Mol. Cell 1: 277-287.
49. Zhao, M., J. Zhang, H. Phatnani, S. Scheu, and T. Maniatis. 2012. Stochastic expression of the interferon-β gene. PLoS Biol. 10: e1001249.
50. Munder, M., F. Mollinedo, J. Calafat, J. Canchado, C. Gil-Lamaignere, J. M. Fuentes, C. Luckner, G. Doschko, G. Soler, K. Eichmann, et al. 2005. Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. Blood 105: 2549-2556.
51. Raes, G., L. Brys, B. K. Dahal, J. Brandt, J. Grooten, F. Brombacher, G. Vanham, W. Noel, P. Bogaert, T. Boonefaes, A. Kindt, R. Van den Bergh, P. J. Leenen, P. De Baetselier, and G. H. Ghassabeh. 2005. Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. J. Leukoc. Biol. 77: 321-327.
52. Raes, G., R. Van den Bergh, P. De Baetselier, G. H. Ghassabeh, C. Scotton, M. Locati, A. Mantovani, and S. Sozzani. 2005. Arginase-1 and Ym1 are markers for murine, but not human, alternatively activated myeloid cells. J. Immunol. 174: 6561.
53. Lumeng, C. N., J. L. Bodzin, and A. R. Saltiel. 2007. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117: 175-184.
54. Morris, D. L., K. Singer, and C. N. Lumeng. 2011. Adipose tissue macrophages: phenotypic plasticity and diversity in lean and obese states. Curr. Opin. Clin. Nutr. Metab. Care 14: 341-346.
55. Feig, J. E., S. Parathath, J. X. Rong, S. L. Mick, Y. Vengrenyuk, L. Grauer, S. G. Young, and E. A. Fisher. 2011. Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques. Circulation 123: 989-998.
56. Wu, D., A. B. Molofsky, H. E. Liang, R. R. Ricardo-Gonzalez, H. A. Jouihan, J. K. Bando, A. Chawla, and R. M. Locksley. 2011. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 332: 243-247.
57. Nguyen, K. D., Y. Qiu, X. Cui, Y. P. Goh, J. Mwangi, T. David, L. Mukundan, F. Brombacher, R. M. Locksley, and A. Chawla. 2011. Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. Nature 480: 104-108.
58. Marigo, I., E. Bosio, S. Solito, C. Mesa, A. Fernandez, L. Dolcetti, S. Ugel, N. Sonda, S. Bicciato, E. Falisi, et al. 2010. Tumor-induced tolerance and immune suppression depend on the C/EBPβ transcription factor. Immunity 32: 790-802.
59. Munera, V., P. J. Popovic, J. Bryk, J. Pribis, D. Caba, B. M. Matta, M. Zenati, and J. B. Ochoa. 2010. Stat6-dependent induction of myeloid derived suppressor cells after physical injury regulates nitric oxide response to endotoxin. Ann. Surg. 251: 120-126.
60. Condamine, T., and D. I. Gabrilovich. 2011. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 32: 19-25.
61. Ochoa, A. C., A. H. Zea, C. Hernandez, and P. C. Rodriguez. 2007. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin. Cancer Res. 13: 721s-726s.
62. Poschke, I., D. Mougiakakos, J. Hansson, G. V. Masucci, and R. Kiessling. 2010. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 70: 4335-4345.
63. Rodriguez, P. C., D. G. Quiceno, J. Zabaleta, B. Ortiz, A. H. Zea, M. B. Piazuelo, A. Delgado, P. Correa, J. Brayer, E. M. Sotomayor, S. Antonia, J. B. Ochoa, and A. C. Ochoa. 2004. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific Tcell responses. Cancer Res. 64: 5839-5849.